{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:01:39Z","timestamp":1791597699563,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01543-6","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:30:10Z","timestamp":1781505010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence"],"prefix":"10.1038","volume":"10","author":[{"given":"Sebastian","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Campitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Grieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Astsaturov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshabad","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pishvaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios S.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Hosein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Helmstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Maney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hamrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spetzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"1543_CR1","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1543_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1543_CR3","doi-asserted-by":"publisher","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","volume":"7","author":"F Nichetti","year":"2024","unstructured":"Nichetti, F. et al. NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis. JAMA Netw. Open 7, e2350756 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1543_CR4","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272\u20131281 (2023).","journal-title":"Lancet"},{"key":"1543_CR5","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal, D. P. S. et al. Metastatic pancreatic cancer: ASCO Guideline Update. J. Clin. Oncol. 38, 3217\u20133230 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1543_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma, Version 2.2025 2025 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf."},{"key":"1543_CR7","doi-asserted-by":"publisher","first-page":"e2216199","DOI":"10.1001\/jamanetworkopen.2022.16199","volume":"5","author":"A Klein-Brill","year":"2022","unstructured":"Klein-Brill, A., Amar-Farkash, S., Lawrence, G., Collisson, E. A. & Aran, D. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma. JAMA Netw. Open 5, e2216199\u2013e2216199 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1543_CR8","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1097\/MPA.0000000000002299","volume":"53","author":"HT Jeong","year":"2024","unstructured":"Jeong, H. T., Kim, H. G. & Han, J. Efficacy and toxicity of palliative chemotherapy in elderly patients with advanced pancreatic cancer. Pancreas 53, e268\u2013e273 (2024).","journal-title":"Pancreas"},{"key":"1543_CR9","doi-asserted-by":"publisher","first-page":"e2133388","DOI":"10.1001\/jamanetworkopen.2021.33388","volume":"4","author":"MJ Raphael","year":"2021","unstructured":"Raphael, M. J. et al. The association of drug-funding reimbursement with survival outcomes and use of new systemic therapies among patients with advanced pancreatic cancer. JAMA Netw. Open 4, e2133388\u2013e2133388 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1543_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919850367","volume":"11","author":"EG Chiorean","year":"2019","unstructured":"Chiorean, E. G., Cheung, W. Y., Giordano, G., Kim, G. & Al-Batran, S. E. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther. Adv. Med Oncol. 11, 1758835919850367 (2019).","journal-title":"Ther. Adv. Med Oncol."},{"key":"1543_CR11","doi-asserted-by":"crossref","unstructured":"Engelke, J., Klora, M., Zeidler, J., Brand T. FOLFIRINOX versus gemcitabine (plus paclitaxel) for pancreatic cancer\u2014an analysis based on data from the Clinical Cancer Registry of Lower Saxony. Ann. Pancreatic Cancer. 8, 8 (2025).","DOI":"10.21037\/apc-24-36"},{"key":"1543_CR12","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1200\/JCO.24.00936","volume":"43","author":"A Ohba","year":"2025","unstructured":"Ohba, A. et al. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): a randomized, open-label, phase II\/III Trial. J. Clin. Oncol. 43, 3345\u20133354 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1543_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejca.2022.06.042","volume":"174","author":"J Santucci","year":"2022","unstructured":"Santucci, J. et al. Impact of first-line FOLFIRINOX versus Gemcitabine\/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: evidence from the prospective international multicentre PURPLE pancreatic cancer registry. Eur. J. Cancer 174, 102\u2013112 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1543_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.14740\/wjon1604","volume":"14","author":"N Merza","year":"2023","unstructured":"Merza, N. et al. Folfirinox vs. Gemcitabine + Nab-Paclitaxel as the first-line treatment for pancreatic cancer: a systematic review and meta-analysis. World J. Oncol. 14, 325\u2013339 (2023).","journal-title":"World J. Oncol."},{"key":"1543_CR15","doi-asserted-by":"crossref","unstructured":"Pusceddu, S. et al. Comparative effectiveness of gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers 11, 484 (2019).","DOI":"10.3390\/cancers11040484"},{"key":"1543_CR16","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/JCO-25-00436","volume":"43","author":"JJ Knox","year":"2025","unstructured":"Knox, J. J. et al. PASS-01: randomized phase II trial of modified FOLFIRINOX versus Gemcitabine\/Nab-Paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer. J. Clin. Oncol. 43, 3355\u20133368 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1543_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819878660","volume":"12","author":"N Williet","year":"2019","unstructured":"Williet, N. et al. Folfirinox versus gemcitabine\/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Ther. Adv. Gastroenterol. 12, 1756284819878660 (2019).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"1543_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000578","volume":"5","author":"I Pokataev","year":"2020","unstructured":"Pokataev, I. et al. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open 5, e000578 (2020).","journal-title":"ESMO Open"},{"key":"1543_CR19","doi-asserted-by":"crossref","unstructured":"Wenric, S. et al. Real-world validation of the purity independent subtyping of tumors classifier for informing therapy selection in pancreatic ductal adenocarcinoma. JCO Precis. Oncol. 9, e2500197 (2025).","DOI":"10.1200\/PO-25-00197"},{"key":"1543_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","volume":"26","author":"NU Rashid","year":"2020","unstructured":"Rashid, N. U. et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clin. Cancer Res. 26, 82\u201392 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1543_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.annonc.2024.06.010","volume":"35","author":"N Fraunhoffer","year":"2024","unstructured":"Fraunhoffer, N. et al. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Ann. Oncol. 35, 780\u2013791 (2024).","journal-title":"Ann. Oncol."},{"key":"1543_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1437200","volume":"14","author":"N Fraunhoffer","year":"2024","unstructured":"Fraunhoffer, N. et al. Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer. Front. Oncol. 14, 1437200 (2024).","journal-title":"Front. Oncol."},{"key":"1543_CR23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.gastro.2022.11.035","volume":"164","author":"N Fraunhoffer","year":"2023","unstructured":"Fraunhoffer, N. et al. A Transcriptomic-based tool to predict gemcitabine sensitivity in advanced pancreatic adenocarcinoma. Gastroenterology 164, 476\u201380.e4 (2023).","journal-title":"Gastroenterology"},{"key":"1543_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.annonc.2020.10.601","volume":"32","author":"R Nicolle","year":"2021","unstructured":"Nicolle, R. et al. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Ann. Oncol. 32, 250\u2013260 (2021).","journal-title":"Ann. Oncol."},{"key":"1543_CR25","unstructured":"Hendifar, A. E. et al. Development and validation of a computational histology artificial intelligence\u2013powered predictive biomarker for selection of chemotherapy in advanced pancreatic cancer. J. Clin. Oncol. JCO2502199 (2026)."},{"key":"1543_CR26","doi-asserted-by":"publisher","first-page":"e2453588","DOI":"10.1001\/jamanetworkopen.2024.53588","volume":"8","author":"C Norton","year":"2025","unstructured":"Norton, C. et al. KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. JAMA Netw. Open 8, e2453588 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1543_CR27","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO-25-01786","volume":"43","author":"T Seufferlein","year":"2025","unstructured":"Seufferlein, T. Personalizing chemotherapy in metastatic pancreatic cancer. J. Clin. Oncol. 43, 3327\u20133330 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1543_CR28","doi-asserted-by":"publisher","first-page":"e2134458","DOI":"10.1001\/jamanetworkopen.2021.34458","volume":"4","author":"NH Tran","year":"2021","unstructured":"Tran, N. H. & Bekaii-Saab, T. Optimizing chemotherapy choice in the treatment of advanced pancreatic cancer\u2014it is complicated. JAMA Netw. Open 4, e2134458\u2013e2134458 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1543_CR29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40273-018-0678-6","volume":"36","author":"M Gharaibeh","year":"2018","unstructured":"Gharaibeh, M. et al. Economic evaluation for USA of systemic chemotherapies as first-line treatment of metastatic pancreatic cancer. Pharmacoeconomics 36, 1273\u20131284 (2018).","journal-title":"Pharmacoeconomics"},{"key":"1543_CR30","first-page":"1367","volume":"27","author":"AA Kharat","year":"2021","unstructured":"Kharat, A. A., Nelson, R., Au, T. & Biskupiak, J. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials. J. Manag Care Spec. Pharm. 27, 1367\u20131375 (2021).","journal-title":"J. Manag Care Spec. Pharm."},{"key":"1543_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.36469\/jheor.2025.142403","volume":"12","author":"S Dennen","year":"2025","unstructured":"Dennen, S., Masek, M., Cockrum, P. & Nagelhout, E. Paluri R. Costs of first-line treatment with FOLFIRINOX, modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. J. Health Econ. Outcomes Res. 12, 75\u201384 (2025).","journal-title":"J. Health Econ. Outcomes Res."},{"key":"1543_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","volume":"31","author":"AM Varghese","year":"2025","unstructured":"Varghese, A. M. et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat. Med. 31, 466\u2013477 (2025).","journal-title":"Nat. Med."},{"key":"1543_CR33","doi-asserted-by":"publisher","first-page":"EVIDoa2300144","DOI":"10.1056\/EVIDoa2300144","volume":"3","author":"A Carrato","year":"2024","unstructured":"Carrato, A. et al. Nab-Paclitaxel plus Gemcitabine and FOLFOX in metastatic pancreatic cancer. NEJM Evid. 3, EVIDoa2300144 (2024).","journal-title":"NEJM Evid."},{"key":"1543_CR34","doi-asserted-by":"publisher","first-page":"LBA4004-LBA","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA4004","volume":"43","author":"M Reni","year":"2025","unstructured":"Reni, M. et al. Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. J. Clin. Oncol. 43, LBA4004-LBA (2025).","journal-title":"J. Clin. Oncol."},{"key":"1543_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100441","volume":"10","author":"MM Steiniche","year":"2025","unstructured":"Steiniche, M. M. et al. Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis. J. Liq. Biopsy 10, 100441 (2025).","journal-title":"J. Liq. Biopsy"},{"key":"1543_CR36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2025.43.4_suppl.690","volume":"43","author":"P Cockrum","year":"2025","unstructured":"Cockrum, P. et al. Overall survival (OS) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line (1L) FOLFIRINOX (FFX): bridging the gap between the NAPOLI 3 trial and real-world practice. J. Clin. Oncol. 43, 690 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1543_CR37","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","volume":"391","author":"T Gilbert","year":"2018","unstructured":"Gilbert, T. et al. Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet 391, 1775\u20131782 (2018).","journal-title":"Lancet"},{"key":"1543_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.18632\/oncotarget.28761","volume":"16","author":"V Domenyuk","year":"2025","unstructured":"Domenyuk, V. et al. Clinical and analytical validation of MI Cancer Seek\u00ae, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay. Oncotarget 16, 642\u2013659 (2025).","journal-title":"Oncotarget"},{"key":"1543_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1543_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"1543_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygyno.2025.04.586","volume":"197","author":"E Evans","year":"2025","unstructured":"Evans, E. et al. Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors. Gynecol. Oncol. 197, 139\u2013145 (2025).","journal-title":"Gynecol. Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01543-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:01:54Z","timestamp":1787677314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01543-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01543-6","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C., P.C., A.H., D.M., J.R.R., J.H., and D.S. are employees of Caris Life Sciences with stock and\/or stock options in the company. H.S. (for last two years): Consulting: Blueprint medicines, Dewpoint Therapeutics, Zola Therapeutics; Honoraria: Uptodate; Research funds: Astrazeneca. MJP (for last two years): Consultant\/Ad Hoc Advisory: Merus, Serna Bio, Revolution Medicines, Boerhinger Ingelheim; Steering Committee: Astellas, RenovoRx; Travel: Merus, Revolution Medicines; Stock: Perthera; Research funding (to institution): Arcus Bio, Ideaya, Repare Tx, Novartis, Pfizer, Merck, Tizonia, Amgen, Boerhinger Ingelheim, Astellas, Actuate, MEI Pharma, Elevation Oncology, Recursion Pharma, Eli Lilly, Parabalis. BG: Consulting\/Travel: Agenus, Lilly, Pfizer. TSB: Research Funding (to institution): Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS, Revolution Medicine; Consulting (to institution): Servier, Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merus, Merck KGaA, Revolution Medicines, Merck; Consulting (to self): Stemline, AbbVie, Blueprint Medicines, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, Takeda, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, Astra Zeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine, Sanofi, Glaxo SmithKline, Xilio and RYGHT Ai; IDMC\/DSMB: The Valley Hospital, Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck\/Eisai, PanCan and 1Globe; Scientific Advisory Board: Imugene, Immuneering, Xilis, Replimune, Artiva, Sun Biopharma; Royalties: Uptodate; Patents: WO\/2018\/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF \u2013 Licensed to Imugene, WO\/2019\/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA \u2013 Licensed to Recursion. D.V.H.: Stock\/Ownership: Medtronic, SynDevRx, United Healthcare, Stromatis Pharma, Systems Oncology, StingRay, Halia Therapeutics, Lycia Therapeutics, (3+2) Pharma, AcuViz, Blossom Hill, Elevance Health; Consulting\/Advisory Role: Imaging Endpoints, CanBas, Lixte Biotechnology, TD2, Phosplatin Therapeutics, SOTIO, Immunophotonics, Novita Pharmaceuticals, Sirnaomics, AiMed Bio, Pfizer, ImmuneOncia, Viracta Therapeutics, AlaMab, Xerient, Lycia Therapeutics, EXACT Therapeutics, ImagineAB, SignaBlok, Compass Therapeutics, Sellas Life Sciences, SMP Oncology, Red Arrow Therapeutics, Soley Therapeutics, Invios GmbH, Peptomyc, Remunity, Panavance Therapeutics, CyMon Bio, Bryologyx, Moleculin Biotech, EnGeneIC, Race Oncology, Autonomix, Econic Biosciences, Crinetics Pharmaceuticals, Diaknons Research, Improve Bio, Duo Oncology, ImmuVia, WUGEN Inc, Origin Commercial Advisors, Civala, Immuneering, SHY Therapeutics; Research Funding (to institution): Minneamrita Therapeutics; Patents\/Royalties: Intramedullary Catheter, Methods of Human Prostate Cancer. I.A.: Consulting\/Advisory Role: Caris Life Sciences. P.A.P.: honoraria: Revolution Medicine, Corcept, Incyte; Consulting\/Advisory Role: Novocure; DSMB: J-Pharma, Oncolytic Bioscience; Research Funding: G.E., Novartis, BMS, Taiho Pharmaceutical. P.J.H.: Consulting\/Advisory Role: Fibrogen, Betaglue Therapeutics, Revolution Medicines.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"329"}}